SLC5A2 and diabetic kidney disease: Another potential limitation is that the mechanisms by which signaling downstream of SGLT2 affects the intracellular pathways described herein remain unclear; however, we proposed several mechanisms by which ipragliflozin ameliorates the progression of early diabetic nephropathy in rodents.